clomipramine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
substances of the imipramine group 701 303-49-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clomipramine
  • chlorimipramine
  • clomipramine hydrochloride
  • clomipramine HCl
A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
  • Molecular weight: 314.86
  • Formula: C19H23ClN2
  • CLOGP: 5.92
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.34
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.24 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 51 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 26 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1989 FDA MALLINCKRODT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 242.73 16.29 148 11172 64216 63413486
Intentional overdose 230.82 16.29 151 11169 74001 63403701
Serotonin syndrome 176.42 16.29 91 11229 28591 63449111
Drug interaction 150.12 16.29 194 11126 228937 63248765
Poisoning deliberate 142.82 16.29 59 11261 11159 63466543
Overdose 142.33 16.29 136 11184 114942 63362760
Suicide attempt 133.21 16.29 100 11220 60818 63416884
Bezoar 120.87 16.29 32 11288 1494 63476208
Intentional self-injury 104.26 16.29 62 11258 25625 63452077
Toxicity to various agents 100.18 16.29 167 11153 247083 63230619
Depressed level of consciousness 87.54 16.29 79 11241 61999 63415703
Sopor 86.06 16.29 52 11268 22112 63455590
Antipsychotic drug level increased 83.52 16.29 29 11291 3406 63474296
Neuroleptic malignant syndrome 79.16 16.29 40 11280 12016 63465686
Electrocardiogram QT prolonged 74.71 16.29 71 11249 59459 63418243
International normalised ratio abnormal 65.59 16.29 24 11296 3280 63474422
Altered state of consciousness 65.52 16.29 46 11274 25184 63452518
Agitation 65.15 16.29 66 11254 59691 63418011
Tachycardia 64.91 16.29 92 11228 118064 63359638
Antidepressant drug level increased 63.28 16.29 14 11306 302 63477400
Suicidal ideation 62.75 16.29 66 11254 62355 63415347
Pain 62.69 16.29 27 11293 740601 62737101
Tremor 59.80 16.29 94 11226 132145 63345557
Hyperthermia 56.10 16.29 29 11291 9127 63468575
Somnolence 54.74 16.29 107 11213 178578 63299124
Drug abuse 54.64 16.29 66 11254 72452 63405250
Hypertonia 54.34 16.29 23 11297 4614 63473088
Sinus tachycardia 53.34 16.29 40 11280 24228 63453474
Myoclonus 50.93 16.29 33 11287 15835 63461867
Cerebellar syndrome 49.77 16.29 20 11300 3519 63474183
Polyuria 46.50 16.29 25 11295 8517 63469185
Akathisia 44.90 16.29 25 11295 9121 63468581
Psychomotor hyperactivity 43.93 16.29 26 11294 10637 63467065
Hypotension 43.86 16.29 127 11193 272477 63205225
Livedo reticularis 42.18 16.29 16 11304 2416 63475286
Joint swelling 41.26 16.29 5 11315 327661 63150041
Confusional state 39.83 16.29 112 11208 236268 63241434
Arthralgia 39.05 16.29 27 11293 569683 62908019
Ventricular dyskinesia 38.66 16.29 8 11312 124 63477578
Hyposmia 38.29 16.29 11 11309 696 63477006
Alopecia 38.25 16.29 7 11313 337529 63140173
Hyperchloraemia 37.46 16.29 11 11309 752 63476950
Mental disorder 36.53 16.29 33 11287 25886 63451816
Hepatocellular injury 34.98 16.29 33 11287 27348 63450354
Parkinsonism 34.22 16.29 22 11298 10417 63467285
Fatigue 34.09 16.29 67 11253 887961 62589741
Pneumonia aspiration 33.76 16.29 36 11284 34504 63443198
Poisoning 33.30 16.29 24 11296 13676 63464026
Diarrhoea 32.92 16.29 48 11272 715318 62762384
Urinary retention 32.15 16.29 33 11287 30268 63447434
Hypotonia 31.50 16.29 20 11300 9265 63468437
Mydriasis 31.50 16.29 22 11298 11934 63465768
Restlessness 31.12 16.29 32 11288 29421 63448281
Blood prolactin increased 30.17 16.29 14 11306 3489 63474213
Drug withdrawal syndrome neonatal 30.09 16.29 12 11308 2069 63475633
Muscle rigidity 29.92 16.29 21 11299 11479 63466223
Cor pulmonale acute 29.74 16.29 8 11312 397 63477305
Dialysis 29.39 16.29 20 11300 10407 63467295
Post-anoxic myoclonus 29.38 16.29 5 11315 24 63477678
Newborn persistent pulmonary hypertension 28.87 16.29 7 11313 228 63477474
Psychomotor skills impaired 28.59 16.29 12 11308 2356 63475346
Inappropriate antidiuretic hormone secretion 28.57 16.29 23 11297 15439 63462263
Heat stroke 27.93 16.29 9 11311 839 63476863
Miosis 27.88 16.29 17 11303 7336 63470366
Disturbance in attention 27.52 16.29 34 11286 38155 63439547
Urine osmolarity increased 27.09 16.29 6 11314 130 63477572
Otorrhoea 26.89 16.29 10 11310 1429 63476273
Drug level increased 26.40 16.29 26 11294 22710 63454992
Mania 26.32 16.29 20 11300 12347 63465355
Product dose omission issue 26.22 16.29 5 11315 234308 63243394
Retroplacental haematoma 25.97 16.29 6 11314 158 63477544
Psychomotor retardation 25.87 16.29 13 11307 3857 63473845
Contraindicated product administered 25.77 16.29 4 11316 217644 63260058
Shock 25.71 16.29 26 11294 23437 63454265
Hallucination, auditory 25.68 16.29 20 11300 12804 63464898
Nasopharyngitis 25.32 16.29 7 11313 254250 63223452
Circulatory collapse 25.31 16.29 25 11295 21913 63455789
Obsessive-compulsive disorder 25.28 16.29 13 11307 4047 63473655
Treatment failure 25.12 16.29 3 11317 199040 63278662
Vertigo 24.88 16.29 41 11279 59846 63417856
Cyanosis 24.73 16.29 22 11298 16913 63460789
Onychophagia 24.50 16.29 5 11315 72 63477630
Stereotypy 24.49 16.29 7 11313 435 63477267
Lactic acidosis 24.29 16.29 32 11288 38255 63439447
Arthropathy 24.26 16.29 6 11314 234786 63242916
Therapeutic product effect decreased 24.17 16.29 3 11317 193184 63284518
Postnatal growth restriction 24.10 16.29 4 11316 16 63477686
Spasmodic dysphonia 24.07 16.29 5 11315 79 63477623
Peripheral swelling 23.53 16.29 9 11311 265933 63211769
Rash 23.51 16.29 40 11280 560831 62916871
Swelling 23.26 16.29 10 11310 275368 63202334
Electrocardiogram QRS complex prolonged 23.21 16.29 14 11306 5924 63471778
Nephrogenic diabetes insipidus 22.94 16.29 8 11312 951 63476751
Hyponatraemia 22.85 16.29 57 11263 111843 63365859
Apathy 22.74 16.29 16 11304 8778 63468924
Asphyxia 22.70 16.29 14 11306 6167 63471535
Hypokalaemia 22.39 16.29 54 11266 103750 63373952
Drug hypersensitivity 22.22 16.29 14 11306 310673 63167029
Rheumatoid arthritis 21.78 16.29 9 11311 253810 63223892
Paralogism 21.75 16.29 4 11316 32 63477670
Infection 21.56 16.29 7 11313 229166 63248536
Tardive dyskinesia 20.91 16.29 15 11305 8487 63469215
Cholestasis 20.87 16.29 26 11294 29408 63448294
Foetal arrhythmia 20.30 16.29 5 11315 174 63477528
Right ventricular dilatation 20.12 16.29 8 11312 1368 63476334
Hypernatraemia 20.04 16.29 14 11306 7595 63470107
Anxiety 19.79 16.29 84 11236 217457 63260245
Drug screen false positive 19.71 16.29 7 11313 877 63476825
Abdominal discomfort 19.65 16.29 17 11303 320868 63156834
Hyperhidrosis 19.01 16.29 52 11268 107784 63369918
Loss of consciousness 18.91 16.29 55 11265 118066 63359636
Acquired haemophilia 18.66 16.29 7 11313 1024 63476678
Respiratory depression 18.42 16.29 17 11303 13698 63464004
Hyporesponsive to stimuli 18.20 16.29 7 11313 1097 63476605
Rhabdomyolysis 18.13 16.29 30 11290 43921 63433781
Morbid thoughts 18.05 16.29 6 11314 617 63477085
Completed suicide 17.98 16.29 62 11258 145611 63332091
Headache 17.78 16.29 56 11264 633185 62844517
Otitis media 17.76 16.29 11 11309 4880 63472822
Premature baby 17.47 16.29 20 11300 20715 63456987
Toxic skin eruption 17.36 16.29 16 11304 12869 63464833
Hyperprolactinaemia 17.36 16.29 10 11310 3890 63473812
Psychiatric symptom 17.10 16.29 11 11309 5212 63472490
Drug intolerance 16.98 16.29 18 11302 308643 63169059
Intestinal gangrene 16.92 16.29 3 11317 19 63477683
Junctional ectopic tachycardia 16.91 16.29 4 11316 117 63477585
Hepatic cytolysis 16.74 16.29 17 11303 15390 63462312
Generalised tonic-clonic seizure 16.50 16.29 23 11297 28993 63448709

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Antipsychotic drug level below therapeutic 352.81 20.97 89 8546 2458 34945838
Suicide attempt 351.93 20.97 178 8457 38938 34909358
Therapeutic product effect variable 346.05 20.97 87 8548 2369 34945927
Obsessive-compulsive disorder 339.27 20.97 102 8533 5462 34942834
Disinhibition 336.68 20.97 90 8545 3136 34945160
Euphoric mood 308.00 20.97 95 8540 5546 34942750
Akathisia 289.69 20.97 99 8536 8010 34940286
Increased appetite 266.54 20.97 91 8544 7338 34940958
Toxicity to various agents 154.88 20.97 217 8418 200145 34748151
Intentional overdose 127.26 20.97 97 8538 43577 34904719
Leukaemia 121.77 20.97 45 8590 4558 34943738
Therapeutic product effect incomplete 112.72 20.97 96 8539 50445 34897851
Serotonin syndrome 110.45 20.97 66 8569 19867 34928429
Dyslipidaemia 110.27 20.97 48 8587 7440 34940856
Coma 104.38 20.97 88 8547 45590 34902706
Leukopenia 104.08 20.97 101 8534 62755 34885541
Weight increased 98.56 20.97 118 8517 92915 34855381
Obesity 96.61 20.97 52 8583 12826 34935470
Prescribed overdose 94.15 20.97 48 8587 10599 34937697
Electrocardiogram QT prolonged 93.76 20.97 79 8556 40873 34907423
Neuroleptic malignant syndrome 93.21 20.97 57 8578 17877 34930419
Poisoning deliberate 92.32 20.97 43 8592 7801 34940495
Intentional self-injury 69.58 20.97 43 8592 13728 34934568
Sopor 61.58 20.97 38 8597 12098 34936198
Schizoaffective disorder 54.45 20.97 18 8617 1309 34946987
Extrapyramidal disorder 49.78 20.97 34 8601 12846 34935450
Somnolence 49.42 20.97 94 8541 111022 34837274
Agitation 48.30 20.97 65 8570 57334 34890962
Overdose 42.92 20.97 79 8556 90980 34857316
Irritability 41.40 20.97 40 8595 24650 34923646
Drug interaction 40.42 20.97 135 8500 225811 34722485
Compartment syndrome 40.08 20.97 18 8617 3000 34945296
Renal hypertension 38.99 20.97 9 8626 168 34948128
Dermatitis bullous 38.52 20.97 23 8612 6899 34941397
Loose associations 35.89 20.97 7 8628 55 34948241
Fatigue 35.69 20.97 24 8611 370629 34577667
Drug ineffective 35.12 20.97 212 8423 456539 34491757
Mania 34.15 20.97 24 8611 9487 34938809
Brachial plexus injury 34.03 20.97 7 8628 74 34948222
Hypertonia neonatal 30.33 20.97 9 8626 458 34947838
Tremor 29.68 20.97 64 8571 82523 34865773
Aggression 29.57 20.97 42 8593 38922 34909374
Hypothermia 29.34 20.97 23 8612 10725 34937571
Pneumonia 29.24 20.97 28 8607 362599 34585697
Rhabdomyolysis 28.22 20.97 56 8579 68107 34880189
Adrenergic syndrome 26.86 20.97 6 8629 96 34948200
Cough 26.61 20.97 3 8632 150137 34798159
Pain 26.13 20.97 9 8626 204666 34743630
Hyperthermia 25.40 20.97 21 8614 10556 34937740
Feelings of worthlessness 24.49 20.97 7 8628 312 34947984
Bradykinesia 24.47 20.97 14 8621 3879 34944417
Death 24.41 20.97 38 8597 398011 34550285
Suicidal ideation 24.20 20.97 39 8596 40349 34907947
Coma scale abnormal 24.09 20.97 14 8621 3994 34944302
Inappropriate antidiuretic hormone secretion 23.93 20.97 22 8613 12731 34935565
Febrile neutropenia 23.59 20.97 3 8632 136846 34811450
Dyspnoea 23.07 20.97 36 8599 376746 34571550
Arthralgia 22.53 20.97 7 8628 170034 34778262
Dyspraxia 22.32 20.97 7 8628 430 34947866
Diarrhoea 22.25 20.97 39 8596 389873 34558423
Hallucination, auditory 21.28 20.97 20 8615 11897 34936399
Cogwheel rigidity 20.98 20.97 9 8626 1343 34946953

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 342.56 16.48 228 16054 100421 79627685
Suicide attempt 309.30 16.48 199 16083 82733 79645373
Intentional overdose 306.13 16.48 217 16065 105743 79622363
Serotonin syndrome 270.25 16.48 147 16135 44880 79683226
Poisoning deliberate 220.24 16.48 97 16185 18731 79709375
Neuroleptic malignant syndrome 179.37 16.48 95 16187 27464 79700642
Drug interaction 162.81 16.48 298 15984 414885 79313221
Overdose 159.35 16.48 192 16090 184014 79544092
Toxicity to various agents 155.81 16.48 295 15987 421245 79306861
Sopor 145.04 16.48 88 16194 32922 79695184
Electrocardiogram QT prolonged 144.59 16.48 131 16151 90255 79637851
Bezoar 132.15 16.48 40 16242 2648 79725458
Intentional self-injury 118.72 16.48 77 16205 32342 79695764
Akathisia 116.44 16.48 56 16226 13203 79714903
Obsessive-compulsive disorder 101.18 16.48 40 16242 5887 79722219
Somnolence 99.08 16.48 176 16106 238805 79489301
Agitation 91.13 16.48 107 16175 99608 79628498
Antipsychotic drug level below therapeutic 85.55 16.48 24 16258 1214 79726892
Hyperthermia 84.17 16.48 50 16232 17987 79710119
Suicidal ideation 80.07 16.48 88 16194 76252 79651854
Therapeutic product effect variable 74.09 16.48 24 16258 1985 79726121
Depressed level of consciousness 72.63 16.48 94 16188 96558 79631548
Disinhibition 71.87 16.48 25 16257 2573 79725533
Tremor 71.37 16.48 126 16156 169957 79558149
Altered state of consciousness 70.96 16.48 64 16218 43758 79684348
Pain 68.69 16.48 29 16253 703773 79024333
Euphoric mood 62.93 16.48 31 16251 7695 79720411
Antidepressant drug level increased 61.46 16.48 15 16267 437 79727669
Tachycardia 61.21 16.48 121 16161 177647 79550459
Mania 61.07 16.48 41 16241 18219 79709887
Psychomotor hyperactivity 56.76 16.48 38 16244 16811 79711295
Antipsychotic drug level increased 54.86 16.48 26 16256 5931 79722175
Rhabdomyolysis 52.02 16.48 83 16199 103048 79625058
Fatigue 51.45 16.48 69 16213 929658 78798448
Arthralgia 50.47 16.48 27 16255 571776 79156330
Confusional state 50.42 16.48 161 16121 317836 79410270
Parkinsonism 50.17 16.48 35 16247 16549 79711557
International normalised ratio abnormal 49.54 16.48 24 16258 5744 79722362
Shock 45.29 16.48 50 16232 43498 79684608
Diarrhoea 44.12 16.48 70 16212 880419 78847687
Myoclonus 43.99 16.48 40 16242 27620 79700486
Hepatocellular injury 43.32 16.48 51 16231 47542 79680564
Sinus tachycardia 42.99 16.48 45 16237 36863 79691243
Extrapyramidal disorder 42.49 16.48 36 16246 22643 79705463
Inappropriate antidiuretic hormone secretion 41.74 16.48 38 16244 26275 79701831
Cerebellar syndrome 41.71 16.48 21 16261 5459 79722647
Joint swelling 41.69 16.48 5 16277 288641 79439465
Polyuria 41.52 16.48 30 16252 14984 79713122
Hallucination, auditory 41.15 16.48 34 16248 20659 79707447
Nasopharyngitis 40.36 16.48 3 16279 253878 79474228
Pneumonia aspiration 39.54 16.48 58 16224 66909 79661197
Psychomotor retardation 39.31 16.48 21 16261 6163 79721943
Renal hypertension 39.04 16.48 9 16273 204 79727902
Dyslipidaemia 38.61 16.48 26 16256 11607 79716499
Schizoaffective disorder 38.40 16.48 15 16267 2137 79725969
Muscle rigidity 38.15 16.48 32 16250 19850 79708256
Peripheral swelling 38.13 16.48 5 16277 269612 79458494
Increased appetite 37.92 16.48 26 16256 11952 79716154
Drug abuse 37.11 16.48 94 16188 162597 79565509
Loose associations 36.89 16.48 7 16275 58 79728048
Hypertonia 36.24 16.48 21 16261 7211 79720895
Prescribed overdose 35.15 16.48 41 16241 37842 79690264
Mydriasis 35.11 16.48 29 16253 17614 79710492
Compartment syndrome 34.41 16.48 18 16264 5064 79723042
Irritability 34.03 16.48 42 16240 41102 79687004
Dermatitis bullous 33.88 16.48 26 16256 14219 79713887
Apathy 33.78 16.48 25 16257 12952 79715154
Circulatory collapse 33.68 16.48 40 16242 37628 79690478
Infusion related reaction 33.21 16.48 4 16278 230233 79497873
Obesity 32.56 16.48 38 16244 35087 79693019
Brachial plexus injury 32.44 16.48 7 16275 116 79727990
Livedo reticularis 32.04 16.48 16 16266 4087 79724019
Hyperchloraemia 31.83 16.48 11 16271 1110 79726996
Hyposmia 31.75 16.48 10 16272 755 79727351
Bradykinesia 31.65 16.48 20 16262 8023 79720083
Loss of consciousness 31.23 16.48 90 16192 167853 79560253
Seizure 31.15 16.48 97 16185 188737 79539369
Mental disorder 30.93 16.48 35 16247 31267 79696839
Urinary retention 30.51 16.48 47 16235 56583 79671523
Bronchial hyperreactivity 30.25 16.48 14 16268 3026 79725080
Hyperhidrosis 29.94 16.48 83 16199 151409 79576697
Completed suicide 29.03 16.48 113 16169 245654 79482452
Abulia 28.93 16.48 10 16272 1010 79727096
Febrile neutropenia 28.85 16.48 6 16276 230993 79497113
Generalised tonic-clonic seizure 28.82 16.48 40 16242 43870 79684236
Ventricular dyskinesia 28.60 16.48 8 16274 400 79727706
Electrocardiogram QRS complex prolonged 28.49 16.48 21 16261 10812 79717294
Coma scale abnormal 27.86 16.48 19 16263 8659 79719447
Product dose omission issue 27.85 16.48 8 16274 247529 79480577
Miosis 27.42 16.48 24 16258 15765 79712341
Heat stroke 27.35 16.48 11 16271 1692 79726414
Pressure of speech 27.11 16.48 10 16272 1218 79726888
Restlessness 27.06 16.48 40 16242 46452 79681654
Blood prolactin increased 26.57 16.48 14 16268 3997 79724109
Retroplacental haematoma 26.55 16.48 6 16276 124 79727982
Hypotension 26.50 16.48 167 16115 440150 79287956
Post-anoxic myoclonus 26.29 16.48 5 16277 42 79728064
Rash 26.13 16.48 49 16233 578309 79149797
Cough 26.03 16.48 22 16260 366767 79361339
Social anxiety disorder 25.95 16.48 8 16274 563 79727543
Drug level increased 25.84 16.48 36 16246 39615 79688491
Adrenergic syndrome 25.50 16.48 6 16276 149 79727957
Breast disorder 25.22 16.48 11 16271 2070 79726036
Hypothermia 25.19 16.48 27 16255 22719 79705387
Alopecia 25.08 16.48 8 16274 231347 79496759
Speech disorder 24.97 16.48 42 16240 54403 79673703
Asphyxia 24.87 16.48 20 16262 11700 79716406
Pneumonia 24.82 16.48 62 16220 660184 79067922
Withdrawal syndrome 24.80 16.48 29 16253 26825 79701281
Abdominal pain 24.56 16.48 26 16256 389543 79338563
Poisoning 24.53 16.48 28 16254 25244 79702862
Pain in extremity 24.50 16.48 23 16259 364515 79363591
Clonus 24.42 16.48 16 16266 6824 79721282
Cor pulmonale acute 24.39 16.48 8 16274 688 79727418
Aggression 24.30 16.48 40 16242 50918 79677188
Psychiatric symptom 24.01 16.48 16 16266 7019 79721087
Intentional product misuse 23.82 16.48 57 16225 95108 79632998
Otorrhoea 23.71 16.48 10 16272 1735 79726371
Arthropathy 23.39 16.48 4 16278 177107 79550999
Therapeutic product effect decreased 23.25 16.48 3 16279 163860 79564246
Disturbance in attention 23.05 16.48 39 16243 50762 79677344
Leukopenia 22.19 16.48 63 16219 116450 79611656
Abnormal behaviour 22.15 16.48 32 16250 36389 79691717
Onychophagia 22.05 16.48 5 16277 105 79728001
Feelings of worthlessness 22.02 16.48 7 16275 545 79727561
Dyspraxia 21.73 16.48 6 16276 286 79727820
Urine osmolarity increased 21.59 16.48 6 16276 293 79727813
Anxiety 21.47 16.48 104 16178 248408 79479698
Paralogism 21.21 16.48 4 16278 32 79728074
Dialysis 20.59 16.48 22 16260 18440 79709666
Psychomotor skills impaired 20.55 16.48 13 16269 5224 79722882
Blood creatine phosphokinase increased 20.36 16.48 43 16239 66047 79662059
Pleurothotonus 20.20 16.48 10 16272 2506 79725600
Stomatitis 20.08 16.48 3 16279 146754 79581352
Contraindicated product administered 19.85 16.48 4 16278 157534 79570572
Headache 19.75 16.48 68 16214 653704 79074402
Hepatic cytolysis 19.74 16.48 26 16256 27125 79700981
Disorientation 19.52 16.48 41 16241 62735 79665371
Hypersensitivity 19.50 16.48 15 16267 262224 79465882
Morbid thoughts 19.45 16.48 7 16275 795 79727311
Swelling 19.41 16.48 10 16272 216701 79511405
Hypernatraemia 19.35 16.48 19 16263 14432 79713674
Sepsis 19.30 16.48 16 16266 269412 79458694
Hyperreflexia 19.27 16.48 15 16267 8370 79719736
Obsessive-compulsive symptom 19.18 16.48 5 16277 191 79727915
Death 19.16 16.48 56 16226 566458 79161648
Vertigo 19.06 16.48 43 16239 69039 79659067
Infection 19.05 16.48 13 16269 241699 79486407
Drug hypersensitivity 18.77 16.48 20 16262 298896 79429210
Nephrogenic diabetes insipidus 18.69 16.48 9 16273 2125 79725981
Hypokalaemia 18.45 16.48 68 16214 143972 79584134
Product use in unapproved indication 18.30 16.48 100 16182 250259 79477847
Treatment failure 18.29 16.48 6 16276 170480 79557626
Rheumatoid arthritis 18.11 16.48 10 16272 208460 79519646
Abdominal discomfort 17.82 16.48 15 16267 250712 79477394
Nausea 17.58 16.48 119 16163 957077 78771029
Depression 17.49 16.48 89 16193 216701 79511405
Spasmodic dysphonia 17.45 16.48 5 16277 273 79727833
Stupor 17.35 16.48 13 16269 6859 79721247
Drug screen false positive 17.25 16.48 7 16275 1102 79727004
Anticholinergic syndrome 16.81 16.48 10 16272 3601 79724505
Right ventricular dilatation 16.50 16.48 8 16274 1918 79726188

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA04 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:48278 serotonergic drugs
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:149553 anticoronaviral drug
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D017367 Selective Serotonin Reuptake Inhibitors
MeSH PA D018490 Serotonin Agents
FDA EPC N0000175752 Tricyclic Antidepressant
CHEBI has role CHEBI:50949 SSRI
CHEBI has role CHEBI:77402 EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Obsessive-compulsive disorder indication 191736004 DOID:10933
Depressive disorder off-label use 35489007
Cataplexy off-label use 46263000
Anxiety off-label use 48694002
Panic disorder off-label use 371631005 DOID:594
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Glaucoma contraindication 23986001 DOID:1686
Hyperthyroidism contraindication 34486009 DOID:7998
Acute nephropathy contraindication 58574008
Epilepsy contraindication 84757009 DOID:1826
Bipolar affective disorder, current episode manic contraindication 191618007
Disease of liver contraindication 235856003 DOID:409
Retention of urine contraindication 267064002
Pheochromocytoma contraindication 302835009
Malignant hyperthermia contraindication 405501007
Myocardial infarction in recovery phase contraindication 418044006
Neuroblastoma contraindication 432328008 DOID:769
Atrioventricular Conduction Defect contraindication




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Separation anxiety Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Clomicalm Tablets Virbac AH Inc. 1
Clomipramine Hydrochloride Tablets Mizner Bioscience LLC 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 6.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 9.70 PDSP CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 7.42 WOMBAT-PK IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 6.28 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.24 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 7.45 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 6.82 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.19 PDSP
5-hydroxytryptamine receptor 6 GPCR Ki 6.95 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 8.50 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.34 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.41 PDSP
Histamine H1 receptor GPCR Ki 8.01 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.70 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 7.66 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.07 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7.44 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.89 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 7.42 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 6.32 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.69 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter IC50 5.56 CHEMBL
Cytochrome P450 2D6 Enzyme Ki 5.66 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.40 DRUG MATRIX
Glutathione S-transferase P Enzyme WOMBAT-PK
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel IC50 5.05 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.71 CHEMBL
D(1A) dopamine receptor GPCR Ki 6.66 PDSP
D(2) dopamine receptor GPCR Ki 6.95 PDSP
Trypanothione reductase Enzyme Ki 5.19 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 7.14 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.94 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 10.40 CHEMBL
D(2) dopamine receptor GPCR Ki 7.25 CHEMBL
Sodium-dependent noradrenaline transporter Transporter IC50 6.05 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 7.15 CHEMBL
Histamine H1 receptor GPCR IC50 9.70 CHEMBL
Serotonin (5-HT) receptor GPCR IC50 8.30 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 5.30 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.29 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 8.08 CHEMBL
Trypanothione reductase Enzyme IC50 5.47 CHEMBL
G protein-activated inward rectifier potassium channel 2 Ion channel BLOCKER IC50 4.40 IUPHAR

External reference:

IDSource
4019687 VUID
N0000147779 NUI
D00811 KEGG_DRUG
17321-77-6 SECONDARY_CAS_RN
2597 RXNORM
4019492 VANDF
4019687 VANDF
C0009010 UMLSCUI
CHEBI:47780 CHEBI
CXX PDB_CHEM_ID
CHEMBL415 ChEMBL_ID
DB01242 DRUGBANK_ID
CHEMBL1200710 ChEMBL_ID
D002997 MESH_DESCRIPTOR_UI
2801 PUBCHEM_CID
2398 IUPHAR_LIGAND_ID
2238 INN_ID
NUV44L116D UNII
373 MMSL
4476 MMSL
d00876 MMSL
003456 NDDF
004614 NDDF
372903001 SNOMEDCT_US
387027004 SNOMEDCT_US
96209002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3025 CAPSULE 25 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3050 CAPSULE 50 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3075 CAPSULE 75 mg ORAL ANDA 25 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8806 CAPSULE 25 mg ORAL NDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8807 CAPSULE 50 mg ORAL NDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8808 CAPSULE 75 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9906 CAPSULE 25 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9907 CAPSULE 50 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9908 CAPSULE 75 mg ORAL NDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2027 CAPSULE 25 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2037 CAPSULE 50 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0630 CAPSULE 25 mg ORAL ANDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0630 CAPSULE 25 mg ORAL ANDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0631 CAPSULE 50 mg ORAL ANDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0631 CAPSULE 50 mg ORAL ANDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0632 CAPSULE 75 mg ORAL ANDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0632 CAPSULE 75 mg ORAL ANDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7038 CAPSULE 25 mg ORAL ANDA 26 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7039 CAPSULE 50 mg ORAL ANDA 26 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-698 CAPSULE 25 mg ORAL ANDA 27 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-699 CAPSULE 50 mg ORAL ANDA 27 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-700 CAPSULE 75 mg ORAL ANDA 27 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-683 CAPSULE 25 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-684 CAPSULE 50 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-685 CAPSULE 75 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-849 CAPSULE 25 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-849 CAPSULE 25 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-850 CAPSULE 50 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-850 CAPSULE 50 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-851 CAPSULE 75 mg ORAL ANDA 21 sections